Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06482905 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
A Phase 1 study of High Grade Glioma and WHO Grade Ⅳ Glioma, sponsored by Tcelltech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 4
- Study locations
NCT06482905 is a Phase 1 study of High Grade Glioma and WHO Grade Ⅳ Glioma that is actively recruiting participants, run by Tcelltech. The registered enrollment target is 52 participants, below the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target (19% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06482905, a Phase 1 study of High Grade Glioma and WHO Grade Ⅳ Glioma, is actively recruiting participants, sponsored by Tcelltech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Conditions Studied
Interventions
- BIOLOGICAL Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
Study Locations (4)
Arizona
- Mayo Clinic in Arizona - Phoenix
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Beijing Municipality
- Beijing Tiantan Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06482905
The ClinicalTrials.gov registry entry for NCT06482905 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target (19% lower). The listed sponsor is Tcelltech, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 is the first listed.
NCT06482905 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06482905 about?
NCT06482905 is a clinical study titled "Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.". This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) a...
What is the current status of trial NCT06482905?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2024-09-04. Estimated completion is 2027-06.
What conditions does trial NCT06482905 study?
This clinical trial studies the following conditions: High Grade Glioma, WHO Grade Ⅳ Glioma.
What interventions are being tested in trial NCT06482905?
The interventions under investigation include: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06482905?
This trial is sponsored by Tcelltech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06482905 being conducted?
This trial has 4 study locations across Arizona, Florida, Minnesota, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
RECRUITING · Phase 1
-
STARLITE for Unresectable High-Grade Gliomas
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.